Summary:
- Eli Lilly, a major pharmaceutical company, has pledged £279 million to establish a new biotechnology hub in the UK. This investment aims to bolster the company's research and development efforts in the country.
- The new hub will focus on developing treatments for obesity, a growing global health concern. Lilly plans to collaborate with the UK government and academic institutions to advance research and innovation in this field.
- The investment is part of Lilly's broader strategy to expand its presence and capabilities in the UK, a key market for the company's pharmaceutical products and research activities.